Fitbit is broadening access to its experimental features program while simultaneously deepening its health tracking capabilities, according to announcements from the Google-owned wearable company this week.

The Fitbit Public Preview program, which allows users to test new features before their official release, is now available in additional countries beyond its initial launch markets. The expansion comes alongside the introduction of VO2 Max measurements and integration with U.S. electronic health records—two features that position Fitbit more directly against competitors like Apple Watch and Garmin in the clinical health monitoring space.

Building Out the Beta Ecosystem

The Public Preview program has evolved significantly since its introduction, initially limiting experimental features to premium subscribers. According to reporting by 9to5Google, Fitbit recently made the program accessible to free users and has added core tracking functions including water intake and food logging to the testing pipeline.

This democratization of beta access reflects a strategic shift in how Google approaches feature development for Fitbit devices. By opening experimental tools to a broader user base, the company gains more diverse feedback while building goodwill among cost-conscious consumers who have been reluctant to commit to subscription services.

The international expansion also addresses a persistent criticism of Fitbit's rollout strategy. Health and fitness features often launch in the United States first, leaving users in other markets waiting months or even years for parity. While the company has not disclosed the complete list of newly added countries, the move suggests an effort to develop features with global applicability from earlier stages.

VO2 Max Enters the Mainstream

The addition of VO2 Max tracking represents Fitbit's entry into a measurement that has become increasingly standard among serious fitness wearables. VO2 Max—the maximum rate of oxygen consumption during exercise—serves as a key indicator of cardiovascular fitness and has been linked to long-term health outcomes in clinical research.

Apple introduced VO2 Max estimation to the Apple Watch in 2020, while Garmin has offered the metric on its devices for years. Fitbit's implementation arrives at a moment when such measurements are transitioning from niche athletic tools to mainstream health indicators that appeal to casual users seeking objective fitness benchmarks.

The technical challenge lies in accuracy. Consumer wearables estimate VO2 Max through algorithms that analyze heart rate data during physical activity, rather than the gold-standard laboratory test that requires specialized equipment. How Fitbit's calculations compare to competitors and clinical measurements will likely determine whether the feature becomes a meaningful differentiator or merely a checkbox specification.

Health Records Integration Signals Clinical Ambitions

Perhaps more significant is Fitbit's integration with U.S. health records systems—a feature that positions the platform as a bridge between consumer wellness tracking and clinical medicine. The integration reportedly allows users to import medical data directly into the Fitbit ecosystem, creating a more comprehensive health profile.

This capability aligns with broader industry trends toward interoperability in digital health. In the United States, regulations including the 21st Century Cures Act have pushed healthcare providers to make patient data more accessible through standardized APIs. Technology companies have moved quickly to capitalize on this opening, with Apple Health Records launching in 2018 and now supporting hundreds of healthcare institutions.

For Fitbit, the timing is strategic. Google's acquisition of the company for $2.1 billion in 2021 raised immediate questions about data privacy and the tech giant's intentions in the healthcare space. By building clinical integrations carefully—and limiting the initial rollout to the heavily regulated U.S. market—Fitbit can demonstrate utility while navigating complex privacy frameworks.

The approach also creates potential revenue pathways beyond hardware sales and premium subscriptions. Aggregated, anonymized health data holds significant value for research institutions and pharmaceutical companies, though any such monetization would require transparent consent frameworks to avoid regulatory and public backlash.

Competitive Pressures Mount

These feature additions arrive as Fitbit faces intensifying competition across multiple fronts. Apple continues to dominate the premium smartwatch segment, while Samsung has gained ground with its Galaxy Watch line. Meanwhile, budget-focused competitors from Chinese manufacturers have eroded Fitbit's position in entry-level fitness tracking.

Google's stewardship of the Fitbit brand has produced mixed results. The company has integrated Fitbit data with Google's health platforms and maintained the brand's identity rather than absorbing it entirely into the Pixel ecosystem. However, market share data suggests Fitbit has struggled to reverse declining sales trends that predated the acquisition.

The Public Preview expansion represents a relatively low-cost strategy to maintain user engagement and generate positive coverage. By framing new features as collaborative experiments rather than finished products, Fitbit can manage expectations while gathering real-world usage data that informs final implementations.

Whether these incremental improvements translate to renewed market momentum remains uncertain. The wearable health market has matured considerably, with most interested consumers already owning devices and replacement cycles extending as hardware quality improves. Success may depend less on feature parity with competitors and more on Fitbit's ability to create unique value propositions that justify continued ecosystem investment.

For now, the company appears committed to broadening its user base geographically while deepening its health tracking capabilities—a dual strategy that acknowledges both the global nature of the wearables market and the clinical credibility required to differentiate in an increasingly crowded field.